Haoran Xia

机构：Nanjing University · ORCID：0000-0002-4040-3061

发表论文 49 篇 · 总被引 1004 次 · h-index 13

代表论文

• Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing (2023 · Genome Medicine · 被引 400)
• Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer (2024 · Nature Genetics · 被引 146)
• Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial (2022 · BMC Medicine · 被引 68)
• Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study (2023 · Nature Communications · 被引 46)
• Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study (2024 · Signal Transduction and Targeted Therapy · 被引 35)
• Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer (2023 · eLife · 被引 22)